Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Projects Holdings, Inc.BSLK · Entity 65458 | Director | August 13, 2024 | August 15, 2024 |
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Financial Officer | September 15, 2022 | September 19, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Projects Holdings, Inc.
Report date August 13, 2024 · Filed August 15, 2024
This filing explicitly reported no securities owned.
Tyra Biosciences, Inc.
Report date September 15, 2022 · Filed September 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 121,897 |
Reported balance
After 2022-09-15 transaction · row 1
1 source rowRow 1 · 2022-09-15 · Grant · Acquired 1,452 · Balance 121,897 F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 118,645 |
Reported balance
Holding disclosure · report date 2022-09-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 118,645 F2: Represents shares held by van den Boom Ventures LLC, of which the spouse of the Reporting Person is the managing member. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Represents shares held by van den Boom Ventures LLC, of which the spouse of the Reporting Person is the managing member.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2022 Filed Sep 19, 2022 22:17 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,452 | $7.66 | $11,120.14 |
DisclosureSEC source: 0001209191-22-050613 · doc4.xml · nonDerivative · entry 1 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,897 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 89,054 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049219 · doc4.xml · derivative · entry 4 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,054 Underlying: Common Stock · 89,054 shares Expires 2032-09-05 F4 · derivative.exercise_date: 1/36th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-22-049219 · doc4.xml · derivative · entry 3 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2032-09-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following September 6, 2022, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 15, 2022 Filed Sep 8, 2022 21:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantCommon Stock | 1,800 | $8.53 | $15,345.90 |
DisclosureSEC source: 0001209191-22-049219 · doc4.xml · nonDerivative · entry 1 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,445 F1 · kind: These shares were acquired under the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:59 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063023 · doc4.xml · derivative · entry 3 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:59 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 7,964 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063023 · doc4.xml · derivative · entry 2 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,964 Underlying: Common Stock · 7,964 shares Expires 2031-11-01 F2 · derivative.exercise_date: The option vests based on achievement of a performance objective. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 23:59 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | GrantStock Option (Right to Buy) · Derivative | 83,626 | $0.00 Strike: $24.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063023 · doc4.xml · derivative · entry 1 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,626 Underlying: Common Stock · 83,626 shares Expires 2031-11-01 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following November 2, 2021, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionSeries A Preferred Stock · Derivative | 8,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036427 · doc4.xml · derivative · entry 3 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 17, 2021 Filed Sep 17, 2021 20:44 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | ConversionCommon Stock | 21,254 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-036427 · doc4.xml · nonDerivative · entry 1 van den Boom Esther · CIK 0001603563 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 21,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.nature: Represents shares held by van den Boom Ventures LLC, of which the spouse of the Reporting Person is the managing member. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.